$JSPR
Jasper Therapeutics, Inc. Stock $jspr

$jspr Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000121390022071165 Filed on November 10, 2022

Income Statement

Concept	2022 Q3	2021 Q3
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.686M	$2.891M
YoY Change	27.5%	1212.36%
% of Gross Profit
Research & Development	$9.022M	$7.188M
YoY Change	25.51%	59.03%
% of Gross Profit
Depreciation & Amortization	$268.0K	$132.0K
YoY Change	103.03%
% of Gross Profit
Operating Expenses	$12.71M	$10.08M
YoY Change	26.08%	4475.33%
Operating Profit	-$12.71M	-$10.08M
YoY Change	26.08%
Interest Expense	$0.00	-$9.000K
YoY Change	-100.0%	-182.72%
% of Operating Profit
Other Income/Expense, Net	$845.0K	$6.676M
YoY Change	-87.34%
Pretax Income	-$11.86M	-$3.412M
YoY Change	247.68%	1529.34%
Income Tax
% Of Pretax Income
Net Earnings	-$11.86M	-$3.412M
YoY Change	247.68%	1595.91%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.32	-$0.69
Diluted Earnings Per Share	-$0.32	-$90.23K
COMMON SHARES
Basic Shares Outstanding	36.57M shares	4.966M shares
Diluted Shares Outstanding	36.57M shares	4.966M shares

Balance Sheet

Concept	2022 Q3	2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$50.95M	$100.9M
YoY Change	-49.51%	13220.44%
Cash & Equivalents	$50.95M	$100.9M
Short-Term Investments
Other Short-Term Assets	$430.0K	$1.204M
YoY Change	-64.29%	484.49%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$117.0K
Total Short-Term Assets	$52.41M	$102.4M
YoY Change	-48.82%	10528.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.759M	$4.461M
YoY Change	-15.74%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$543.0K
YoY Change
Total Long-Term Assets	$6.699M	$4.806M
YoY Change	39.39%	-95.21%
TOTAL ASSETS
Total Short-Term Assets	$52.41M	$102.4M
Total Long-Term Assets	$6.699M	$4.806M
Total Assets	$59.11M	$107.2M
YoY Change	-44.87%	5.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.117M	$2.247M
YoY Change	38.72%	1203.06%
Accrued Expenses	$3.488M	$6.442M
YoY Change	-45.86%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.421M	$9.159M
YoY Change	-18.98%	4978.46%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$707.0K	$19.45M
YoY Change	-96.37%	455.77%
Total Long-Term Liabilities	$707.0K	$19.45M
YoY Change	-96.37%	455.77%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.421M	$9.159M
Total Long-Term Liabilities	$707.0K	$19.45M
Total Liabilities	$11.55M	$28.61M
YoY Change	-59.65%	677.4%
SHAREHOLDERS EQUITY
Retained Earnings	-$91.92M
YoY Change
Common Stock	$4.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$47.57M	$78.60M
YoY Change
Total Liabilities & Shareholders Equity	$59.11M	$107.2M
YoY Change	-44.87%	5.82%

Cashflow Statement

Concept	2022 Q3	2021 Q3
OPERATING ACTIVITIES
Net Income	-$11.86M	-$3.412M
YoY Change	247.68%	1595.91%
Depreciation, Depletion And Amortization	$268.0K	$132.0K
YoY Change	103.03%
Cash From Operating Activities	-$9.643M	-$7.108M
YoY Change	35.66%	3005.29%
INVESTING ACTIVITIES
Capital Expenditures	-$222.0K	-$470.0K
YoY Change	-52.77%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$222.0K	-$470.0K
YoY Change	-52.77%	-751.15%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.000K	91.73M
YoY Change	-100.0%
NET CHANGE
Cash From Operating Activities	-9.643M	-7.108M
Cash From Investing Activities	-222.0K	-470.0K
Cash From Financing Activities	1.000K	91.73M
Net Change In Cash	-9.864M	84.15M
YoY Change	-111.72%	-53793.21%
FREE CASH FLOW
Cash From Operating Activities	-$9.643M	-$7.108M
Capital Expenditures	-$222.0K	-$470.0K
Free Cash Flow	-$9.421M	-$6.638M
YoY Change	41.93%	2799.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39138
	dei	Entity Registrant Name EntityRegistrantName	JASPER THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q3	us-gaap	Liabilities Liabilities	11545000	usd
CY2022Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	543000	usd
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-2984849
	dei	Entity Address Address Line1 EntityAddressAddressLine1	2200 Bridge Pkwy
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite #102
	dei	Entity Address City Or Town EntityAddressCityOrTown	Redwood City
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94065
	dei	City Area Code CityAreaCode	(650)
	dei	Local Phone Number LocalPhoneNumber	549-1400
	dei	Security12b Title Security12bTitle	Voting Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	JSPR
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50950000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	84701000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1461000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3130000	usd
CY2022Q3	us-gaap	Assets Current AssetsCurrent	52411000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	87831000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3759000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3686000	usd
CY2022Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1980000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1147000	usd
CY2022Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	417000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	345000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	645000	usd
CY2022Q3	us-gaap	Assets Assets	59110000	usd
CY2021Q4	us-gaap	Assets Assets	93654000	usd
CY2022Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3117000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3919000	usd
CY2022Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	840000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	505000	usd
CY2022Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3464000	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3596000	usd
CY2022Q3	us-gaap	Liabilities Current LiabilitiesCurrent	7421000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8020000	usd
CY2022Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3014000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2380000	usd
CY2022Q3	jspr	Common Stock Warrant Liability CommonStockWarrantLiability	300000	usd
CY2021Q4	jspr	Common Stock Warrant Liability CommonStockWarrantLiability	7350000	usd
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7188000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25345000	usd
CY2022Q3	jspr	Earnout Liability EarnoutLiability	103000	usd
CY2021Q4	jspr	Earnout Liability EarnoutLiability	5743000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	707000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	643000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16764000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3686000	usd
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2891000	usd
CY2022Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9022000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	24136000	usd
CY2022Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	492000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	492000000	shares
CY2022Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37984368	shares
CY2022Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37984368	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37855114	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37855114	shares
CY2022Q3	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	4000	usd
CY2022Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	139485000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	136964000	usd
CY2022Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-91924000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-67450000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	47565000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	69518000	usd
CY2022Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	59110000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	93654000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12104000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7987000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	12708000	usd
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	10079000	usd
	us-gaap	Operating Expenses OperatingExpenses	37449000	usd
	us-gaap	Operating Expenses OperatingExpenses	24751000	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-12708000	usd
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10079000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-37449000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-24751000	usd
CY2022Q3	jspr	Change In Fair Value Of Earnout Liability ChangeInFairValueOfEarnoutLiability	-422000	usd
CY2021Q3	jspr	Change In Fair Value Of Earnout Liability ChangeInFairValueOfEarnoutLiability	-6226000	usd
	jspr	Change In Fair Value Of Earnout Liability ChangeInFairValueOfEarnoutLiability	-5640000	usd
	jspr	Change In Fair Value Of Earnout Liability ChangeInFairValueOfEarnoutLiability	-6226000	usd
CY2022Q3	jspr	Change In Fair Value Of Common Stock Warrant Liability ChangeInFairValueOfCommonStockWarrantLiability	-155000	usd
CY2021Q3	jspr	Change In Fair Value Of Common Stock Warrant Liability ChangeInFairValueOfCommonStockWarrantLiability	-450000	usd
	jspr	Change In Fair Value Of Common Stock Warrant Liability ChangeInFairValueOfCommonStockWarrantLiability	-7050000	usd
	jspr	Change In Fair Value Of Common Stock Warrant Liability ChangeInFairValueOfCommonStockWarrantLiability	-450000	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	3501000	usd
CY2022Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	268000	usd
CY2021Q3	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-9000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	285000	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-4000	usd
CY2022Q3	us-gaap	Other Income OtherIncome	845000	usd
CY2021Q3	us-gaap	Other Income OtherIncome	6667000	usd
	us-gaap	Other Income OtherIncome	12975000	usd
	us-gaap	Other Income OtherIncome	3171000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-11863000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-3412000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-24474000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21580000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.69
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.67
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-7.13
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36565650	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4966226	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36425000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3028277	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	69518000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	3000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	778000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2207000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	68105000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	2000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1065000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-10404000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	58781000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	2000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	644000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-11863000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	47565000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-35130000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	3000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	327000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-9754000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-44552000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	68000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	2000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	295000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-132000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3072000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-386000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	71000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-8414000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-52601000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	132000	usd
CY2021Q3	jspr	Conversion Of Redeemable Convertible Preferred Stock Into Common Stock In Connection With Rev ConversionOfRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithRev	66249000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	68036000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	3000	usd
CY2021Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	195000	usd
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-3412000	usd
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	78602000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-24474000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21580000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	702000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	183000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	241000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	153000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2487000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	817000	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	3501000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-7050000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-450000	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	5640000	usd
	us-gaap	Liabilities Fair Value Adjustment LiabilitiesFairValueAdjustment	6226000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-1669000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	286000	usd
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	-600000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-102000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-802000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1220000	usd
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-98000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33212000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19094000	usd
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	494000	usd
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	1717000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-494000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1717000	usd
	us-gaap	Proceeds From Hedge Financing Activities ProceedsFromHedgeFinancingActivities	95271000	usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	10750000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	27000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	202000	usd
	jspr	Payment Of Reverse Recapitalization Related Expenses PaymentOfReverseRecapitalizationRelatedExpenses	4345000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	27000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	101878000	usd
CY2022Q3	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	200000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-33679000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	81067000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	85046000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	20183000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51367000	usd
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	101250000	usd
	jspr	Accounts Payable And Accrued Expenses For Purchases Of Property And Equipment AccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment	108000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1074000	usd
	jspr	Noncash Leasehold Improvements NoncashLeaseholdImprovements	281000	usd
	jspr	Noncash Leasehold Improvements NoncashLeaseholdImprovements	1378000	usd
	jspr	Vesting Of Founders Restricted Stock VestingOfFoundersRestrictedStock	7000	usd
	jspr	Vesting Of Founders Restricted Stock VestingOfFoundersRestrictedStock	8000	usd
	jspr	Reverse Recapitalization Related Expenses Unpaid At Period End ReverseRecapitalizationRelatedExpensesUnpaidAtPeriodEnd	651000	usd
	jspr	Conversion Redeemable Convertible Preferred Stock Into Common Stock In Connection With Rev ConversionRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithRev	66249000	usd
	jspr	Net Liabilities Assumed Upon The Closing Reversed Recapitalization NetLiabilitiesAssumedUponTheClosingReversedRecapitalization	7222000	usd
	jspr	Recognition Of Earnout Liabilitys RecognitionOfEarnoutLiabilitys	15020000	usd
	jspr	Settlements Of Derivative Tranche Liability SettlementsOfDerivativeTrancheLiability	11659000	usd
	jspr	Deferred Issuance Costs Reclassified To Additional Paid In Capitals DeferredIssuanceCostsReclassifiedToAdditionalPaidInCapitals	4996000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Description of Business</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Jasper Therapeutics, Inc. (“Jasper” or the “Company”), formerly known as Amplitude Healthcare Acquisition Corporation (“AMHC”), is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. The Company is focused on the development and commercialization of safer and more effective conditioning agents and mRNA-based stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside of the body prior to transplantation. The Company is also developing novel therapeutics directed at diseased hematopoietic stem cells. Its drug development pipeline includes multiple product candidates designed to improve hematopoietic stem cell therapy. The lead product candidate, JSP191, is in clinical development as a novel conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. The Company plans to initiate a registrational clinical study in acute myeloid leukemia patients undergoing stem cell transplantation by the end of the first quarter of 2023. The Company is also initiating a pilot study of JSP191 as a therapeutic in lower-risk myelodysplastic syndrome, which it expects to commence in the first quarter of 2023. The Company is headquartered in Redwood City, California.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On September 24, 2021 (the “Closing Date”), the Company consummated the previously announced business combination (the “Business Combination” or “Reverse Recapitalization” for accounting purposes) pursuant to the terms of the Business Combination Agreement, dated as of May 5, 2021 (the “BCA”), by and among AMHC, Ample Merger Sub, Inc., a then-wholly-owned subsidiary of AMHC (“Merger Sub”), and the pre-Business Combination Jasper Therapeutics, Inc. (now named Jasper Tx Corp.) (“Old Jasper”). Pursuant to the terms of the BCA, on the Closing Date, (i) Merger Sub merged with and into Old Jasper, with Old Jasper as the surviving company in the Business Combination, and, after giving effect to such Business Combination, Old Jasper became a wholly owned subsidiary of AMHC and changed its name to “Jasper Tx Corp.”, and (ii) AMHC changed its name to “Jasper Therapeutics, Inc.”.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, concurrently with the execution of the BCA, certain investors (“PIPE Investors”) entered into Subscription Agreements with AMHC whereby such investors subscribed for the purchase of an aggregate of 10,000,000 shares of AMHC’s Class A Common Stock at a price of $10.00 per share for aggregate gross proceeds of $100.0 million (“PIPE Financing”). The PIPE Financing was consummated concurrently with the closing of the Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Please refer to Note 3, “Reverse Recapitalization”, for further details of the Business Combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Liquidity and Going Concern</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company has incurred significant losses and negative cash flows from operations since its inception. During the nine months ended September 30, 2022 and 2021, the Company incurred net losses of $24.5 million and $21.6 million, respectively. During the nine months ended September 30, 2022 and 2021, the Company had negative operating cash flows of $33.2 million and $19.1 million, respectively. As of September 30, 2022 and December 31, 2021, the Company had an accumulated deficit of $91.9 million and $67.5 million, respectively. The Company expects to continue to incur substantial losses, and its ability to achieve and sustain profitability will depend on the successful development, approval, and commercialization of product candidates and on the achievement of sufficient revenues to support the Company’s cost structure.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company’s cash and cash equivalents of $51.0 million as of September 30, 2022 are not sufficient for the Company to continue as a going concern for at least one year from the issuance date of these condensed consolidated financial statements. Additional funds are necessary to maintain current operations and to continue research and development activities. The Company’s management plans to monitor expenses and raise additional capital through a combination of public and private equity, debt financings, strategic alliances, and licensing arrangements. The Company’s ability to access capital when needed is not assured and, if capital is not available to the Company when, and in the amounts, needed, the Company could be required to delay, scale back or abandon some or all of its development programs and other operations, which could materially harm the Company’s business, financial condition and results of operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The accompanying condensed consolidated financial statements do not reflect any adjustments relating to the recoverability and reclassifications of assets and liabilities that might be necessary if the Company is unable to continue as a going concern.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Coronavirus Pandemic</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In March 2020, the World Health Organization declared the global novel coronavirus disease 2019 (“COVID-19”) outbreak a pandemic. The Company is following, and will continue to follow, recommendations from the U.S. Centers for Disease Control and Prevention as well as federal, state, and local governments regarding working-from-home practices for non-essential employees as well as return-to-work policies and procedures. The Company expects to continue to take actions as may be required or recommended by government authorities or as the Company determines are in the best interests of its employees and other business partners in light of the pandemic.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">While the Company’s operations to date have not been significantly impacted by the COVID-19 pandemic, it cannot at this time predict the specific extent, duration, or full impact that the continuing COVID-19 pandemic will have on its business, financial condition and operations, including ongoing and planned clinical trials and clinical development timelines. The Company experienced slower than anticipated patient enrollment in its severe combined immunodeficiency clinical trial in 2020 due to reluctance of these immunocompromised patients to travel and undergo hospitalization during the pandemic. The Company may continue to experience interruptions to its clinical trials due to the COVID-19 pandemic, including the spread of variants. The impact of the COVID-19 pandemic on the Company’s financial performance will depend on future developments, including the duration and spread of the pandemic, its impact on the Company’s clinical trial enrollment, trial sites, contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”), and other third parties with whom it does business, its impact on regulatory authorities and the Company’s key scientific and management personnel, progress of vaccination and related governmental advisories and restrictions. These developments and the impact of the COVID-19 pandemic on the financial markets and the overall economy are highly uncertain and cannot be predicted.</p>
	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	24500000	usd
	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	21600000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	33200000	usd
	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	19100000	usd
CY2022Q3	us-gaap	Accumulated Capitalized Interest Costs AccumulatedCapitalizedInterestCosts	91900000	usd
CY2021Q4	us-gaap	Accumulated Capitalized Interest Costs AccumulatedCapitalizedInterestCosts	67500000	usd
CY2022Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	51000000	usd
	us-gaap	Convertible Preferred Stock Terms Of Conversion ConvertiblePreferredStockTermsOfConversion	All historical share data and per-share amounts were retrospectively adjusted to reflect the effect of the exchange ratio of 0.2823780 per one share, which was determined at the closing of the Reverse Recapitalization, except for the 100 shares of Series A-2 redeemable convertible preferred stock.
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates, assumptions and judgements that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the valuation of common and redeemable convertible preferred stock before the Reverse Recapitalization, the determination of the incremental borrowing rate used for operating lease liabilities, valuation of derivative liability, valuation of earnout liability and the measurement of stock-based compensation expense. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i> </i></b></p>
	jspr	Business Combination Descriptions BusinessCombinationDescriptions	In accordance with the BCA, at the closing of the Business Combination, each share of Old Jasper common stock and Old Jasper redeemable convertible preferred stock outstanding immediately prior to the closing was automatically cancelled, extinguished and converted into the number of shares of the Company’s common stock or, in certain circumstances, the Company’s non-voting common stock, based on Old Jasper’s equity value of $275.0 million divided by $10.00. The exchange ratio agreed between the parties was one-for-0.282378 share of the Company’s common stock for all Old Jasper stockholders, except for Amgen Inc. (“Amgen”).
CY2022Q3	jspr	Common Stock Represented CommonStockRepresented	0.08	pure
	jspr	Net Proceeds NetProceeds	95300000	usd
	jspr	Cash Held In Trust Account CashHeldInTrustAccount	5500000	usd
	jspr	Cash Received CashReceived	100000000	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1200000	usd
CY2022Q3	us-gaap	Business Acquisition Cost Of Acquired Entity Transaction Costs BusinessAcquisitionCostOfAcquiredEntityTransactionCosts	5300000	usd
CY2022Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	49950000	usd
CY2022Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	49950000	usd
CY2022Q3	jspr	Common Stock Warrant Liabilities CommonStockWarrantLiabilities	300000	usd
CY2022Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	103000	usd
CY2022Q3	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	403000	usd
CY2021Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	83701000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	83701000	usd
CY2021Q4	jspr	Common Stock Warrant Liabilities CommonStockWarrantLiabilities	7350000	usd
CY2021Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5743000	usd
CY2021Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	13093000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	548000	usd
CY2022Q3	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	300000	usd
CY2022Q3	us-gaap	Prepaid Insurance PrepaidInsurance	203000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2074000	usd
CY2022Q3	us-gaap	Other Assets Current OtherAssetsCurrent	430000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	219000	usd
CY2022Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	117000	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	150000	usd
CY2022Q3	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1461000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	444000	usd
CY2021	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	139000	usd
	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	267000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	3130000	usd
CY2022Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2477000	usd
	us-gaap	Equipment Expense EquipmentExpense	1655000	usd
CY2022Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	476000	usd
CY2022Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	140000	usd
CY2022Q3	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	90000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4838000	usd
CY2022Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1079000	usd
CY2022Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3759000	usd
CY2021Q3	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	100000	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	700000	usd
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	200000	usd
CY2022Q3	jspr	Research And Development Accrued Expenses ResearchAndDevelopmentAccruedExpenses	1430000	usd
CY2021Q4	jspr	Research And Development Accrued Expenses ResearchAndDevelopmentAccruedExpenses	1660000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1218000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1151000	usd
CY2021Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	200000	usd
CY2022Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	816000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	585000	usd
CY2022Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	3464000	usd
CY2021Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	3596000	usd
CY2022Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	600000	usd
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	600000	usd
CY2022Q3	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent	95000	usd
CY2022Q3	jspr	Restricted Stock Liabilities RestrictedStockLiabilities	12000	usd
CY2021Q4	jspr	Restricted Stock Liabilities RestrictedStockLiabilities	19000	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	24000	usd
CY2022Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	707000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	643000	usd
CY2020Q4	us-gaap	Restructuring And Related Cost Expected Cost1 RestructuringAndRelatedCostExpectedCost1	2300000	usd
	jspr	Percentage Of Licensing Fees PercentageOfLicensingFees	0.001	pure
	jspr	Fund Technology FundTechnology	1000000	usd
	us-gaap	Debt Conversion Converted Instrument Rate DebtConversionConvertedInstrumentRate	0.60	pure
CY2022Q3	us-gaap	Investment Interest Rate InvestmentInterestRate	0.25	pure
CY2020Q4	jspr	Other Receivables Milestone OtherReceivablesMilestone	600000	usd
CY2020Q4	jspr	Other Longterm Liabilities OtherLongtermLiabilities	600000	usd
CY2021Q1	jspr	Received Aggregate From Cirm ReceivedAggregateFromCIRM	600000	usd
CY2022Q3	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	600000	usd
	us-gaap	Production And Distribution Costs ProductionAndDistributionCosts	1700000	usd
	jspr	Annual License Maintenance Fees Description AnnualLicenseMaintenanceFeesDescription	The Company will pay annual license maintenance fees, beginning on the first anniversary of the effective date of the agreement and ending upon the first commercial sale of a product, method, or service in the licensed field of use, as follows: $25,000 for each first and second year, $35,000 for each third and fourth year, and $50,000 at each anniversary thereafter ending upon the first commercial sale.
	us-gaap	Revenue Recognition Milestone Method Revenue Recognized RevenueRecognitionMilestoneMethodRevenueRecognized	9000000	usd
	jspr	License Maintenance Fee LicenseMaintenanceFee	25000	usd
	us-gaap	Derivative Maturity Dates DerivativeMaturityDates	2026-09-24
CY2021Q3	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	7900000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	129000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	248000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	454000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	336000	usd
CY2021Q3	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	500000	usd
	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	7100000	usd
	us-gaap	Gain Loss On Fair Value Hedges Recognized In Earnings GainLossOnFairValueHedgesRecognizedInEarnings	500000	usd
CY2021Q4	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	300000	usd
	jspr	Contingent Earnout Liabilities Description ContingentEarnoutLiabilitiesDescription	Upon the closing of the Business Combination and pursuant to the Sponsor Support Agreement, the Sponsor agreed to place the Earnout Shares into escrow, which will be released as follows: (a) 250,000 Earnout Shares will be released if, during the period from and after September 24, 2021 until September 24, 2024 (the “Earnout Period”), over any twenty trading days within any thirty day consecutive trading day period, the volume-weighted average price of the Company’s common stock (the “Applicable VWAP”) is greater than or equal to $11.50, (b) 500,000 Earnout Shares will be released if, during the Earnout Period, the Applicable VWAP is greater than or equal to $15.00, and (c) 300,000 Earnout Shares will be released if, during the Earnout Period, the Applicable VWAP is greater than or equal to $18.00 (the “triggering events”).
CY2022Q1	jspr	Rentable Square Feet With Lease Commencement RentableSquareFeetWithLeaseCommencement	5611	sqft
	jspr	Additional Lease Payments For Extra Space AdditionalLeasePaymentsForExtraSpace	1800000	usd
CY2022Q1	jspr	Agreement For Square Feet Of Temporary Office Space AgreementForSquareFeetOfTemporaryOfficeSpace	5144	sqft
	us-gaap	Payments For Rent PaymentsForRent	26000	usd
	jspr	Lessor Amount LessorAmount	400000	usd
	jspr	Improvement Allowance Description ImprovementAllowanceDescription	To complete certain leasehold improvements, the lessor agreed to provide the Company a tenant improvement allowance of $1.5 million as well as an option to take an additional allowance of $0.4 million to be repaid over the lease term at an interest rate of 9% per annum, which the Company exercised.
CY2021Q4	jspr	Leasehold Improvement Gross LeaseholdImprovementGross	1600000	usd
	jspr	Net Construction Costs Percentage NetConstructionCostsPercentage	0.05	pure
	us-gaap	Lease Cost LeaseCost	583000	usd
	us-gaap	Lease Cost LeaseCost	584000	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	594000	usd
	us-gaap	Operating Lease Lease Income Lease Payments OperatingLeaseLeaseIncomeLeasePayments	91100	usd
CY2022Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y10M24D
CY2021Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y9M18D
CY2022Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.08	pure
CY2021Q3	jspr	Common Stock Shares Of Voting CommonStockSharesOfVoting	23482387	shares
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	269000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1121000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1154000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1189000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	743000	usd
CY2022Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	4476000	usd
CY2022Q3	us-gaap	Unrecorded Unconditional Purchase Obligation Imputed Interest UnrecordedUnconditionalPurchaseObligationImputedInterest	622000	usd
CY2022Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	3854000	usd
CY2022Q3	jspr	Current Portion Of Lease Liability CurrentPortionOfLeaseLiability	-840000	usd
CY2022Q3	jspr	Noncurrent Portion Of Lease Liability NoncurrentPortionOfLeaseLiability	3014000	usd
	jspr	Pay Stanford Net PayStanfordNet	900000	usd
	jspr	Pay Stanford Net Term PayStanfordNetTerm	P3Y
CY2020	jspr	First Milestone Agremment FirstMilestoneAgremment	300000	usd
CY2022Q1	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	300000	usd
CY2021Q1	jspr	License Agreements Description LicenseAgreementsDescription	In March 2021, the Company entered into the Stanford License Agreement (Note 7), pursuant to which the Company is required to pay annual license maintenance fees, beginning on the first anniversary of the effective date of the agreement and ending upon the first commercial sale of a product, method, or service in the licensed field of use, as follows: $25,000 for each first and second year, $35,000 for each third and fourth year, and $50,000 at each anniversary thereafter ending upon the first commercial sale. The Company is also obligated to pay late-stage clinical development milestones and first commercial sales milestone payments of up to $9.0 million in total.
CY2022Q1	us-gaap	Direct Taxes And Licenses Costs DirectTaxesAndLicensesCosts	25000	usd
CY2021Q3	jspr	Shares Of Nonvoting Common Stock SharesOfNonvotingCommonStock	1296022	shares
CY2022Q3	us-gaap	Excess Stock Shares Authorized ExcessStockSharesAuthorized	490000000	shares
	us-gaap	Preferred Stock Dividends Shares PreferredStockDividendsShares	10000000	shares
	jspr	Common Stock Voting Shares CommonStockVotingShares	37073346	shares
	jspr	Common Stock Nonvoting Shares CommonStockNonvotingShares	911022	shares
CY2022Q3	jspr	Outstanding And Issued Common Stock Option OutstandingAndIssuedCommonStockOption	6279930	shares
CY2021Q4	jspr	Outstanding And Issued Common Stock Option OutstandingAndIssuedCommonStockOption	2660383	shares
	jspr	Common Stock Warrants CommonStockWarrants	4999863	shares
CY2021	jspr	Common Stock Warrants CommonStockWarrants	4999883	shares
CY2022Q3	jspr	Shares Available For Grant Under2021 Equity Incentive Plan SharesAvailableForGrantUnder2021EquityIncentivePlan	-3889106	shares
CY2021Q4	jspr	Shares Available For Grant Under2021 Equity Incentive Plan SharesAvailableForGrantUnder2021EquityIncentivePlan	-4422480	shares
CY2022Q3	jspr	Shares Available For Grant Under2019 Equity Incentive Plan SharesAvailableForGrantUnder2019EquityIncentivePlan	-1295672	shares
CY2022Q3	jspr	Shares Available For Grant Under2021 Employee Stock Purchase Plan SharesAvailableForGrantUnder2021EmployeeStockPurchasePlan	928551	shares
CY2021Q4	jspr	Shares Available For Grant Under2021 Employee Stock Purchase Plan SharesAvailableForGrantUnder2021EmployeeStockPurchasePlan	550000	shares
CY2022Q3	jspr	Outstanding Restricted Stock Units OutstandingRestrictedStockUnits	3125	shares
CY2022Q3	jspr	Total Shares Of Common Stock Reserved TotalSharesOfCommonStockReserved	17396247	shares
CY2021Q4	jspr	Total Shares Of Common Stock Reserved TotalSharesOfCommonStockReserved	12632746	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	The number of shares available for issuance under the 2021 Plan will increase annually in an amount equal to the least of (i) 2,750,000 shares, (ii) a number of shares equal to 4% of the total number of shares of all classes of common stock of the Company outstanding on the last day of the immediately preceding fiscal year, or (iii) such lesser number of shares determined by the Company’s Board of Directors (“Board”) no later than the last day of the immediately preceding fiscal year. The number of shares of common stock available for issuance under the ESPP will increase annually in an amount equal to the least of (i) 550,000 shares of common stock, (ii) a number of shares of common stock equal to 1% of the total number of shares of all classes of common stock of the Company on the last day of the immediately preceding fiscal year, or (iii) such number of shares determined by the Board. As of September 30, 2022, 5,906,146 shares were reserved for issuance under the 2021 Plan, of which 3,889,106 shares were available for future grant and 2,017,040 shares were subject to outstanding options and restricted stock units (“RSUs”), including performance-based awards. As of September 30, 2022, no shares have been issued under the ESPP and 928,551 shares were reserved and available for future issuance.
CY2022Q3	us-gaap	Shares Issued SharesIssued	3000000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1295672	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	1704328	shares
	jspr	Fair Market Value Of Common Stock Percentage FairMarketValueOfCommonStockPercentage	0.85	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage	0.10	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	1.10	pure
	jspr	Nonemployees Generally Vest Term NonemployeesGenerallyVestTerm	P4Y
CY2021Q4	jspr	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grants ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrants	4422480	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2660383	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.81
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y6M14D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	18731908000	usd
CY2022Q3	us-gaap	Preferred Units Authorized PreferredUnitsAuthorized	4514204	shares
	jspr	Shares Available For Grant Options Grantedin Dollars Value SharesAvailableForGrantOptionsGrantedinDollarsValue	-3919553	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3919553	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.37
	jspr	Number Of Shares Options Exercised NumberOfSharesOptionsExercised	-37387	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.71
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	262619	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	262619	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	3.16
CY2022Q3	jspr	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grants ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrants	5279750	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6279930	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.31
	jspr	Weighted Average Remaining Contractual Life Years Ending WeightedAverageRemainingContractualLifeYearsEnding	P8Y18D
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	194469000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6279930	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.31
	us-gaap	Deferred Compensation Arrangement With Individual Maximum Contractual Term1 DeferredCompensationArrangementWithIndividualMaximumContractualTerm1	P8Y18D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	194469000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2104767	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.05
	jspr	Weighted Average Remaining Contractual Life Years Exercisable WeightedAverageRemainingContractualLifeYearsExercisable	P6Y10M2D
CY2022Q3	jspr	Aggregate Intrinsic Value Exercisable AggregateIntrinsicValueExercisable	145143000	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	100000	usd
CY2022Q3	us-gaap	Option Contract Indexed To Equity Settlement Cash Effect Of Change In Fair Value Of Share OptionContractIndexedToEquitySettlementCashEffectOfChangeInFairValueOfShare	1000000	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	1.88
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Exercise Of Stock Options EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions	100000	usd
	us-gaap	Net Amount At Risk By Product And Guarantee Weighted Average Period Remaining1 NetAmountAtRiskByProductAndGuaranteeWeightedAveragePeriodRemaining1	P0Y6M
CY2022Q3	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	475000	usd
CY2021Q3	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	80000	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	1511000	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	337000	usd
CY2022Q3	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	169000	usd
CY2021Q3	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	115000	usd
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	976000	usd
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	480000	usd
CY2022Q3	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	644000	usd
CY2021Q3	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	195000	usd
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	2487000	usd
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	817000	usd
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	100000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	100000	usd
CY2022Q3	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	0	usd
	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	400000	usd
	us-gaap	Net Income Loss Per Outstanding Limited Partnership And General Partnership Unit Basic And Diluted NetIncomeLossPerOutstandingLimitedPartnershipAndGeneralPartnershipUnitBasicAndDiluted	-7.13
CY2022Q3	us-gaap	Weighted Average Basic Shares Outstanding Pro Forma WeightedAverageBasicSharesOutstandingProForma	37983458	shares
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y6M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y6M
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.756	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.756	pure
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0181	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0181	pure
CY2022Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-11863000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3412000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-24474000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-21580000	usd
CY2021Q2	us-gaap	Weighted Average Basic Shares Outstanding Pro Forma WeightedAverageBasicSharesOutstandingProForma	5696303	shares
	us-gaap	Weighted Average Basic Shares Outstanding Pro Forma WeightedAverageBasicSharesOutstandingProForma	37913135	shares
	us-gaap	Weighted Average Basic Shares Outstanding Pro Forma WeightedAverageBasicSharesOutstandingProForma	3775454	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	367808	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	650186	shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	438135	shares
	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	720254	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1050000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	79891	shares
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	1050000	shares
	us-gaap	Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation	26923	shares
CY2022Q3	us-gaap	Weighted Average Number Of Limited Partnership And General Partnership Unit Outstanding Basic And Diluted WeightedAverageNumberOfLimitedPartnershipAndGeneralPartnershipUnitOutstandingBasicAndDiluted	36565650	shares
CY2021Q2	us-gaap	Weighted Average Number Of Limited Partnership And General Partnership Unit Outstanding Basic And Diluted WeightedAverageNumberOfLimitedPartnershipAndGeneralPartnershipUnitOutstandingBasicAndDiluted	4966226	shares
	us-gaap	Weighted Average Number Of Limited Partnership And General Partnership Unit Outstanding Basic And Diluted WeightedAverageNumberOfLimitedPartnershipAndGeneralPartnershipUnitOutstandingBasicAndDiluted	36425000	shares
	us-gaap	Weighted Average Number Of Limited Partnership And General Partnership Unit Outstanding Basic And Diluted WeightedAverageNumberOfLimitedPartnershipAndGeneralPartnershipUnitOutstandingBasicAndDiluted	3028277	shares
CY2022Q3	us-gaap	Net Income Loss Per Outstanding Limited Partnership And General Partnership Unit Basic And Diluted NetIncomeLossPerOutstandingLimitedPartnershipAndGeneralPartnershipUnitBasicAndDiluted	-0.32
CY2021Q2	us-gaap	Net Income Loss Per Outstanding Limited Partnership And General Partnership Unit Basic And Diluted NetIncomeLossPerOutstandingLimitedPartnershipAndGeneralPartnershipUnitBasicAndDiluted	-0.69
	us-gaap	Net Income Loss Per Outstanding Limited Partnership And General Partnership Unit Basic And Diluted NetIncomeLossPerOutstandingLimitedPartnershipAndGeneralPartnershipUnitBasicAndDiluted	-0.67
	jspr	Diluted Net Loss Per Share Attributable To Common Stockholders DilutedNetLossPerShareAttributableToCommonStockholders	11612359	shares
	jspr	Diluted Net Loss Per Share Attributable To Common Stockholders DilutedNetLossPerShareAttributableToCommonStockholders	3333375	shares
CY2022Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	6279930	shares
CY2021Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	2721557	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	6279930	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	2721557	shares
CY2022Q3	jspr	Common Stock Warrants One CommonStockWarrantsOne	4999863	shares
	jspr	Common Stock Warrants One CommonStockWarrantsOne	4999863	shares
CY2022Q3	jspr	Unvested Restricted Common Stock UnvestedRestrictedCommonStock	329441	shares
CY2021Q3	jspr	Unvested Restricted Common Stock UnvestedRestrictedCommonStock	611818	shares
	jspr	Unvested Restricted Common Stock UnvestedRestrictedCommonStock	329441	shares
	jspr	Unvested Restricted Common Stock UnvestedRestrictedCommonStock	611818	shares
CY2022Q3	jspr	Outstanding Rs Us OutstandingRSUs	3125	shares
	jspr	Outstanding Rs Us OutstandingRSUs	3125	shares
CY2022Q3	jspr	Diluted Net Loss Per Share Attributable To Common Stockholders DilutedNetLossPerShareAttributableToCommonStockholders	11612359	shares
CY2021Q3	jspr	Diluted Net Loss Per Share Attributable To Common Stockholders DilutedNetLossPerShareAttributableToCommonStockholders	3333375	shares
	us-gaap	Defined Benefit Plan Significant Transactions Between Employer Or Related Parties And Plan During Year DefinedBenefitPlanSignificantTransactionsBetweenEmployerOrRelatedPartiesAndPlanDuringYear	The Company recorded $0.1 million for the founders’ advisory and consulting services performed for each of the three months ended September 30, 2022 and 2021, and $0.4 million and $0.2 million for the founders’ advisory and consulting services performed for the nine months ended September 30, 2022 and 2021, respectively.
CY2022Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022Q3	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities		usd
CY2021Q3	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities		usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities		usd
CY2022Q1	us-gaap	Stock And Warrants Issued During Period Value Preferred Stock And Warrants StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants		usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022Q2	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2021Q1	jspr	Issuance Of Series A1 Redeemable Convertible Preferred Stock For Cash IssuanceOfSeriesA1RedeemableConvertiblePreferredStockForCash		usd
CY2021Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities		usd
	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets		usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets		usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability		usd
	us-gaap	Proceeds From Hedge Financing Activities ProceedsFromHedgeFinancingActivities		usd
	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock		usd
	jspr	Payment Of Reverse Recapitalization Related Expenses PaymentOfReverseRecapitalizationRelatedExpenses		usd
	jspr	Accounts Payable And Accrued Expenses For Purchases Of Property And Equipment AccountsPayableAndAccruedExpensesForPurchasesOfPropertyAndEquipment		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	jspr	Reverse Recapitalization Related Expenses Unpaid At Period End ReverseRecapitalizationRelatedExpensesUnpaidAtPeriodEnd		usd
	jspr	Conversion Redeemable Convertible Preferred Stock Into Common Stock In Connection With Rev ConversionRedeemableConvertiblePreferredStockIntoCommonStockInConnectionWithRev		usd
	jspr	Net Liabilities Assumed Upon The Closing Reversed Recapitalization NetLiabilitiesAssumedUponTheClosingReversedRecapitalization		usd
	jspr	Recognition Of Earnout Liabilitys RecognitionOfEarnoutLiabilitys		usd
	jspr	Settlements Of Derivative Tranche Liability SettlementsOfDerivativeTrancheLiability		usd
	jspr	Deferred Issuance Costs Reclassified To Additional Paid In Capitals DeferredIssuanceCostsReclassifiedToAdditionalPaidInCapitals		usd
CY2022Q3	us-gaap	Accrued Income Taxes AccruedIncomeTaxes		usd
CY2021Q4	us-gaap	Employee Related Liabilities Current And Noncurrent EmployeeRelatedLiabilitiesCurrentAndNoncurrent		usd
CY2022Q3	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent		usd
CY2022Q3	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue		usd
CY2022Q3	jspr	Estimated Fair Value Of Earnout Liability EstimatedFairValueOfEarnoutLiability		usd
CY2021Q4	jspr	Shares Available For Grant Under2019 Equity Incentive Plan SharesAvailableForGrantUnder2019EquityIncentivePlan		shares
CY2021Q4	jspr	Outstanding Restricted Stock Units OutstandingRestrictedStockUnits		shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Other Share Increase Decrease ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherShareIncreaseDecrease		shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate		pure
CY2021Q3	jspr	Common Stock Warrants One CommonStockWarrantsOne		shares
	jspr	Common Stock Warrants One CommonStockWarrantsOne		shares
CY2021Q3	jspr	Outstanding Rs Us OutstandingRSUs		shares
	jspr	Outstanding Rs Us OutstandingRSUs		shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001788028

Files In Submission

Name	View Source	Status
0001213900-22-071165-index-headers.html	Edgar Link	pending
0001213900-22-071165-index.html	Edgar Link	pending
0001213900-22-071165.txt	Edgar Link	pending
0001213900-22-071165-xbrl.zip	Edgar Link	pending
f10q0922ex10-1_jasperthera.htm	Edgar Link	pending
f10q0922ex31-1_jasperthera.htm	Edgar Link	pending
f10q0922ex31-2_jasperthera.htm	Edgar Link	pending
f10q0922ex32-1_jasperthera.htm	Edgar Link	pending
f10q0922_jasperthera.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
jspr-20220930.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
jspr-20220930_cal.xml	Edgar Link	unprocessable
jspr-20220930_def.xml	Edgar Link	unprocessable
jspr-20220930_lab.xml	Edgar Link	unprocessable
jspr-20220930_pre.xml	Edgar Link	unprocessable
f10q0922_jasperthera_htm.xml	Edgar Link	completed
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$JSPR
Jasper Therapeutics, Inc. Stock $jspr

2022 Q3 Form 10-Q Financial Statement

#000121390022071165 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JSPR Jasper Therapeutics, Inc. Stock $jspr

2022 Q3 Form 10-Q Financial Statement

#000121390022071165 Filed on November 10, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JSPR
Jasper Therapeutics, Inc. Stock $jspr